Fig 3.
Clinical activity with biomarker response in first cycle in a 2-year-old patient with hepatoblastoma. (A) Computed tomography with metastasis outlined in yellow. (B) Follow-up imaging after two doses, with 24% reduction in longest diameter and 54% reduction in volume by three-dimensional volumetric assessment. (C) Alpha fetoprotein decline over first cycle (arrows indicate lexatumumab administration).
